You are receiving this communication because you hold shares of common stock in AnaptysBio, Inc. (“AnaptysBio”). AnaptysBio has released informational materials regarding its spin-off of its biopharma operations business (“First Tracks Biotherapeutics”) that are now available for your review. These materials consist of the Information Statement, plus any supplements, that AnaptysBio has prepared in connection with the spin-off. This notice provides instructions on how to access AnaptysBio materials for informational purposes only. It is not a form for voting and presents only an overview of the AnaptysBio materials, which contain important information and are available, free of charge, on the Internet or by mail. We encourage you to access and review the AnaptysBio materials on the Internet at www.materialnotice.com. AnaptysBio is not asking you for a proxy and you are asked not to send a proxy. The spin-off consists of the proposed distribution of 100% of First Tracks Biotherapeutics shares of common stock to holders of AnaptysBio shares of common stock on a pro rata basis. If you want to receive a paper copy of the informational materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed on the reverse side of this notice.

You may view the materials online at www.materialnotice.com and easily request a paper or e-mail copy (see reverse side).

See the reverse side for instructions on how to access materials.

   Materials Available to VIEW or RECEIVE:

®